Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro

Eli Lilly reported strong GLP-1 momentum, with Mounjaro sales up 125% and Zepbound sales up 80% in Q1 2026, while Mounjaro sales in India still rose 10% despite generic competition. The article highlights international strength, with Morgan Stanley estimating Eli Lilly controls slightly over 50% of the international GLP-1 market. Offset by valuation concerns at about 38x earnings, the piece is constructive on Lilly's growth outlook but not a near-term catalyst.

Analysis

The key signal is not the headline GLP-1 growth rate; it is that pricing power and adherence appear more durable outside the U.S. than the market likely assumes. If a low-cost generic wave in India is not dislodging share, that implies the demand curve is more efficacy-driven than price-elastic at the premium end, which supports a longer runway for the stronger clinical asset rather than just the incumbent brand. That matters because the next leg of value creation is less about unit growth in developed markets and more about whether international mix can offset eventual U.S. normalization.

This also changes the competitive frame versus NVO. The market still treats the race as a simple pill-vs-pill contest, but the more important second-order effect is channel and physician behavior: once prescribers and patients anchor on superior weight-loss outcomes, a less effective oral format may expand category penetration without necessarily winning share from the leader. In other words, oral GLP-1s can grow the TAM while still leaving the best injectable franchise with the higher-value patient cohort, especially if international reimbursement and private-pay markets remain more outcome-sensitive than U.S. managed care.

The biggest contrarian point is that the stock may deserve a valuation premium even after rerating, because the market is likely underwriting U.S. saturation while underappreciating ex-U.S. duration. The real risk is not another weak quarter; it is a longer-dated efficacy surprise from a future Lilly oral/next-gen asset, or policy/regulatory pressure that compresses premium pricing faster than volume can scale. On the downside, if international growth decelerates after generic penetration normalizes, the multiple likely de-rates first and the earnings revision follows 1-2 quarters later.

Key Decisions for Investors

• Stay long LLY on any 3-5% pullback over the next 2-6 weeks; use India/international share resilience as evidence that downside from generic erosion is overstated. Risk/reward: limited fundamental downside unless growth inflects lower, but upside remains tied to long-duration international mix and next-gen pipeline.
• Pair trade: long LLY / short NVO for a 3-9 month horizon. Thesis: market is overpricing NVO's oral wedge versus Lilly's superior efficacy and international share resilience; this is a cleaner relative-value expression than outright long exposure.
• Avoid chasing NVO on pill headlines until there is proof of share transfer in ex-U.S. markets. If using options, prefer selling NVO upside calls against a core position rather than outright directional longs; implied upside looks more consensus-owned than the share data suggests.
• Buy LLY call spreads 6-12 months out if implied volatility remains elevated around GLP-1 headlines. The trade works if international growth stays above consensus and the market re-rates Lilly as a durable global category leader rather than a U.S.-only obesity story.
• Monitor MS for incremental upside bias as the market continues to migrate toward international GLP-1 share leaders. Not a primary trade here, but the read-through supports higher AUM-linked and cross-border revenue assumptions if this category proves more global than domestically centered.